Pharmacopeia

CWP-0078

DEXMEDETOMIDINE

Neurology & Sedation · Level 1

Core pharmacology

Introduction

Central alpha2 agonist
Greater selectivity for A2 than clonidine

Chemical Pharmaceutics

D-stereoisomer

Distribution

Lipid soluble (rapid distribution)

Protein binding

95%

Volume of distribution

2l/kg (steady state)

Metabolism

Hepatic via CYP and glucuronidation
inactive metabolites

Half-life

Large variation in CSHT with infusion length (T1/2 5 minutes after 10 minutes IV, T1/2 240 minutes after 8 hour IV)

Class Group

Highly selective alpha-2 adrenoceptor agonist sedative with sympatholytic properties.

Indications Uses

Sedation of ventilated adult ICU patients and procedural sedation of non-intubated adults. Also used for awake fibreoptic intubation in selected patients.

Presentation

Clear, colourless dexmedetomidine hydrochloride solution for intravenous use. Current Australian product information includes 200 micrograms in 2 mL vials.

Mechanism of action

Specific alpha-2 agonist acting primarily in the locus coeruleus to increase conductance through K+ channels. 8 times more selective than clonidine. Acts on all 3 subtypes of alpha-2R (A, B, C)

Adverse Effects Toxicity

- Transient hypertension (due to peripheral smooth muscle α2B agonism) -> reflex bradycardia Later, hypotension and bradycardia. Rebound HTN on ceasing dose - Dry mouth - nausea

Absorption

Intravenous administration bypasses an absorption phase. For procedural sedation, clinically effective sedation after a loading infusion is typically seen within about 10-15 minutes.

Excretion

Inactive metabolites Excreted in urine

Physiological effects

Produces arousable sedation with minimal respiratory depression. Cardiovascular effects include bradycardia and hypotension, with transient hypertension possible during loading or higher exposure.

Route And Dose

ICU sedation: maintenance infusion generally 0.2-1 microgram/kg/hour, titrated to the required level. A loading dose may be omitted when converting from another sedative. Procedural sedation: loading dose 1 microgram/kg over 10-20 minutes followed by 0.2-1 microgram/kg/hour, titrated to effect.